Bernard Kikaire

Bernard Kikaire

Auto-generated profile, based on publicly available information

Bernard Kikaire

Uganda Virus Research Institute, Uganda

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2021 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
BKBernard Kikaire
Bernard Kikaire
MSMichael Ssemanda
Michael Ssemanda
AAAlex Asiimwe
Alex Asiimwe
MNMiriam Nakanwagi
Miriam Nakanwagi
TRTwaha Rwegyema
Twaha Rwegyema
DBDenis Bwayo
Denis Bwayo
Uniformed service personnel have an increased risk of poor viral load suppression (VLS). This study was performed to evaluate the outcomes of interventions to improve VLS in the 28 military health facilities in Uganda. This operational research was conducted between October 2018 and September 2019, among people living with HIV (PLHIV) in the 28 health facilities managed by the military in Uganda. Patients with a viral load (VL) >1000 copies/ml received three sessions of intensive adherence counselling (IAC), 1 month apart, after which a repeat VL was done. The main outcome was the proportion with a suppressed VL following IAC. Of the 965 participants included in this analysis, 592 (61.4%) were male and 367 (38.3%) were female. Average age was 35.5 ± 13.7 years, and 87.8% had at least one IAC session. At least 48.2% had a suppressed repeat VL. IAC increased the odds of VLS by 82% (P = 0.004), with adjusted OR of 1.56 (P = 0.054). An initial VL >10 000 copies/ml, being on antiretroviral therapy for at least 2 years, being male, and being <18 years of age were associated with repeat VL non-suppression. IAC marginally improved VL suppression. There is a need to improve IAC in military health facilities.

10 March 2022 in IJID Regions
Verified
Journal Article
Open access
AKAnne Kapaata
Anne Kapaata
SBSheila N. Balinda
Sheila N. Balinda
JHJonathan Hare
Jonathan Hare
OLOlga Leonova
Olga Leonova
BKBernard Kikaire
Bernard Kikaire
PKPontiano Kaleebu
Pontiano Kaleebu
The observation that HIV-1 subtype D progresses faster to disease than subtype A prompted us to examine cytokine levels early after infection within the predominant viral subtypes that circulate in Uganda and address the following research questions: (1) Do cytokine levels vary between subtypes A1 and D? (2) Do cytokine profiles correlate with disease outcomes? To address these questions, HIV-1 subtypes were determined by population sequencing of the HIV-1 pol gene and 37 plasma cytokine concentrations were evaluated using V-Plex kits on Meso Scale Discovery platform in 65 recent sero-converters. HIV-1 subtype D (pol) infections exhibited significantly higher median plasma concentrations of IL-5, IL-16, IL-1α, IL-7, IL-17A, CCL11 (Eotaxin-1), CXCL10 (IP-10), CCL13 (MCP-4) and VEGF-D compared to subtype A1 (pol) infections. We also found that IL-12/23p40 and IL-1α were associated with faster CD4+T cell count decline, while bFGF was associated with maintenance of CD4+ counts above 350 cells/microliter. Our results suggest that increased production of cytokines in early HIV infection may trigger a disruption of the immune environment and contribute to pathogenic mechanisms underlying the accelerated disease progression seen in individuals infected with HIV-1 subtype D in Uganda.

17 February 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
MCMatthew J. Cummings
Matthew J. Cummings
BBBarnabas Bakamutumaho
Barnabas Bakamutumaho
JLJulius J. Lutwama
Julius J. Lutwama
NONicholas Owor
Nicholas Owor
XCXiaoyu Che
Xiaoyu Che
MOMax R. O’donnell
Max R. O’donnell
Little is known about the pathobiology of SARS-CoV-2 infection in sub-Saharan Africa, where severe COVID-19 fatality rates are among the highest in the world and the immunological landscape is unique. In a prospective cohort study of 306 adults encompassing the entire clinical spectrum of SARS-CoV-2 infection in Uganda, we profile the peripheral blood proteome and transcriptome to characterize the immunopathology of COVID-19 across multiple phases of the pandemic. Beyond the prognostic importance of myeloid cell-driven immune activation and lymphopenia, we show that multifaceted impairment of host protein synthesis and redox imbalance define core biological signatures of severe COVID-19, with central roles for IL-7, IL-15, and lymphotoxin-α in COVID-19 respiratory failure. While prognostic signatures are generally consistent in SARS-CoV-2/HIV-coinfection, type I interferon responses uniquely scale with COVID-19 severity in persons living with HIV. Throughout the pandemic, COVID-19 severity peaked during phases dominated by A.23/A.23.1 and Delta B.1.617.2/AY variants. Independent of clinical severity, Delta phase COVID-19 is distinguished by exaggerated pro-inflammatory myeloid cell and inflammasome activation, NK and CD8+ T cell depletion, and impaired host protein synthesis. Combining these analyses with a contemporary Ugandan cohort of adults hospitalized with influenza and other severe acute respiratory infections, we show that activation of epidermal and platelet-derived growth factor pathways are distinct features of COVID-19, deepening translational understanding of mechanisms potentially underlying SARS-CoV-2-associated pulmonary fibrosis. Collectively, our findings provide biological rationale for use of broad and targeted immunotherapies for severe COVID-19 in sub-Saharan Africa, illustrate the relevance of local viral and host factors to SARS-CoV-2 immunopathology, and highlight underemphasized yet therapeutically exploitable immune pathways driving COVID-19 severity.

17 December 2023 in BMJ Global Health
Verified
Conference Paper
Open access
PDF file
Annet NanvubyaAnnet Nanvubya
Annet Nanvubya
BKBernard Kikaire
Bernard Kikaire
PKPontiano Kaleebu
Pontiano Kaleebu
Background In April 2010, East African Consortium for Clinical Research (EACCR) in partnership with the University of Oxford initiated the Reciprocal Monitoring Scheme (RMS). This is an innovative, practical and affordable monitoring scheme whose main aim is strategic quality management of health research for the 23 institutions that form the consortium. The main role of the RMS is to oversee the progress of clinical trials while ensuring that they are conducted, recorded, reported in accordance with approved Protocols, Standard Operating Procedures (SOPs), applicable local and international regulatory requirements and Good Clinical Practice. We share our experiences and lessons learnt in the past 13 years. Methods Each institution identified one or two experienced monitors who were paired with unexperienced monitors for mentorship and capacity building. Cross-country pairing was done and monitors were allocated studies to monitor. Physical training was periodically done to refresh skills and brainstorm on experiences. Results A regional pool of 42 monitors were trained and paired from 6 Eastern Africa countries and 5 Northern countries. Seven sponsors have been supported to monitor thirty three (33) studies so far. The scheme offered an opportunity for cross-site sharing of best practices and networking at a cheaper cost compared to using conventional clinical research associates. Dedicating time for monitoring activities remains a big challenge for the study team and monitors. Conclusion Paired monitoring fostered capacity building and maximized sharing of best practices for quality management of internationally recognized health research. Cross-country monitoring visits promoted networking and dialogue between researchers, communities and other stakeholders.

17 December 2023 in BMJ Global Health
Verified
Conference Paper
Open access
PDF file
NKNasimu Kyakuwa
Nasimu Kyakuwa
GKGeofrey Kimbugwe
Geofrey Kimbugwe
SMSimon Mpooya
Simon Mpooya
FNFlavia Nakanjako
Flavia Nakanjako
HKHamza Kalutte
Hamza Kalutte
BKBernard Kikaire
Bernard Kikaire
Background Vaccination is one of the most successful public health interventions for preventing infectious diseases. A successful vaccination program depends on high coverage, and health care workers (HCWs) play a pivotal role in ensuring high uptake of vaccines in the population. COVID-19 vaccines have been proven to be efficacious, and vaccination campaigns have been ongoing, however there is a perceived high vaccine hesitancy even among health care workers in Uganda. This study aimed at describing the facilitators, barriers to and level of uptake of COVID 19 vaccines among healthcare workers in primary healthcare facilities in an urban setting in Uganda. Methods We conducted an online cross-sectional survey among healthcare workers in private and public healthcare facilities in Entebbe municipality between July 2021 and August 2021. Data was collected using an online questionnaire. Uptake of the vaccines among healthcare workers was analysed as proportions, and logistic regression was used to analyse barriers and facilitators to uptake of COVID 19 vaccines. Results The study enrolled 360 participants, with 61.7% (n=222) females. A total of 236 (65.6%) healthcare workers had received at least one dose of COVID 19 vaccine with higher uptake among females 64%(n=151). Age above 40 years (OR 4.29), participating in COVID 19 vaccine related activities (OR 4.18) and having had a negative SARS-COV-2 test result (OR 1.79) increased the odds of having been vaccinated. Working in either a private for profit (OR 0.23) or a private not for profit (OR 0.19) reduced the odds of having been vaccinated. History of having cared for a COVID 19 patient and having a positive SARS-COV-2 test result did not influence the uptake of the vaccines in the study population. Conclusion Vaccine uptake among healthcare workers was close to the World Health Organisation (WHO) recommended uptake of 70% by mid-2022.

17 December 2023 in BMJ Global Health
Verified
Conference Paper
Open access
PDF file
ENEmily Nyanzi
Emily Nyanzi
BWBenjamin Watyaba
Benjamin Watyaba
RWRobert Wangoda
Robert Wangoda
AYAlfred Yayi
Alfred Yayi
SKSamuel Kasibante
Samuel Kasibante
BKBernard Kikaire
Bernard Kikaire
Background Regional Referral Hospitals (RRHs) are mandated by MoH to conduct research to provide evidence-based care to patients, however most lack the knowledge and skills. These provide mostly tertiary care to patients and serve as referrals for several districts under their catchment. Eastern Africa Consortium for Clinical Research (EACCR) through its HIV work package builds capacity for conducting ICH-GCP complaint research in the region. Methods Two RRHs from two regions in Uganda with high volumes of patients were considered: Masaka RRH and Jinja RRH located in Central and Eastern Uganda respectively. Results The needs assessment done to identify the research capacity gaps, showed that the hospitals lacked Institutional review board (IRBs) to guide and evaluate research protocols. Memorandum of understanding were signed between Masaka and Jinja RRHs and the EACCR HIV work package. The parties agreed to train and build capacity of the members of the IRBs to review protocols and establish IRB offices in Masaka and Jinja RRHs. Over 10 staff from each of the two hospitals were trained in good clinical practice, Research management, protocol reviews and research bioethics during pandemics. Masaka RRH had their IRB office refurbished with lockable cabins, a computer, and a printer scanner. The administrators received a one-weeks mentorship attachment to the IRB office at UVRI to learn IRB office operations. The IRB in Masaka and Jinja were guided to develop Standard Operational procedures (SOPs) as reference documents for operations. The IRB Office in Jinja had their office renovated and lockable -movable cabins were installed. All these RRHs are in the process getting accreditation from Uganda National Council of Science and Technology (UNCST). UVRI IRB continues to provide peer mentorship to these two IRBs. Conclusion When accredited, the two hospitals will use the patients and cohorts’ data for health research to answer research questions affecting communities in Uganda.